Trial Profile

In Patients Taking Protease Inhibitors Does Switching to a Bictegravir, Tenofovir Alafenamide and Emtricitabine Combination, Reduce Cardiovascular Risk: an Open-label, Randomised, Serial CT Pilot Study

Status: Withdrawn prior to enrolment

Phase of Trial: Phase IV

Latest Information Update: 20 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary) ; Antiretrovirals
Indications HIV-1 infections
Focus Adverse reactions; Pharmacodynamics
Acronyms HART CT

18 Dec 2024 Planned primary completion date changed from 28 Nov 2020 to 29 Mar 2021.
18 Dec 2024 Status changed from not yet recruiting to withdrawn prior to enrolment (Reason the study was stopped: COVID19 emergency. No patients randomised )
27 Sep 2019 Planned initiation date changed from 6 Aug 2019 to 4 Nov 2019.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com